X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (40) 40
hematology (31) 31
male (31) 31
index medicus (29) 29
female (28) 28
middle aged (27) 27
aged (26) 26
adult (21) 21
oncology (16) 16
aged, 80 and over (15) 15
treatment outcome (14) 14
retrospective studies (11) 11
care and treatment (10) 10
remission induction (9) 9
cancer (8) 8
prognosis (8) 8
adolescent (7) 7
antimetabolites, antineoplastic - therapeutic use (7) 7
azacitidine (7) 7
classification (7) 7
young adult (7) 7
abridged index medicus (6) 6
acute myeloid leukemia (6) 6
azacitidine - therapeutic use (6) 6
essential thrombocythemia (6) 6
follow-up studies (6) 6
leukemia, myeloid, acute - drug therapy (6) 6
leukemia, myeloid, acute - mortality (6) 6
mutation (6) 6
myelodysplastic syndromes (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
apoptosis (5) 5
disease-free survival (5) 5
hematology, oncology and palliative medicine (5) 5
research (5) 5
therapy (5) 5
acute myeloid-leukemia (4) 4
antineoplastic agents - therapeutic use (4) 4
bone marrow - pathology (4) 4
chemotherapy (4) 4
conventional care regimens (4) 4
disease progression (4) 4
elderly (4) 4
hypomethylating agents (4) 4
leukemia (4) 4
polycythemia-vera (4) 4
risk (4) 4
scoring system (4) 4
survival (4) 4
survival rate (4) 4
transplantation (4) 4
acute disease (3) 3
acute leukemia (3) 3
acute myeloid leukaemia (3) 3
analysis (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
chronic myeloproliferative disorders (3) 3
cohort studies (3) 3
cytarabine - administration & dosage (3) 3
development and progression (3) 3
drug therapy (3) 3
further section (3) 3
hematopoietic stem cell transplantation (3) 3
hemic and lymphatic diseases (3) 3
intensive chemotherapy (3) 3
interferon (3) 3
italy (3) 3
jak2 (3) 3
kaplan-meier estimate (3) 3
leukemia, myeloid, acute - genetics (3) 3
methylation (3) 3
myelodysplastic syndrome (3) 3
myelodysplastic syndromes - drug therapy (3) 3
myelodysplastic syndromes - mortality (3) 3
older patients (3) 3
philadelphia chromosome (3) 3
polycythemia vera (3) 3
pyrimidines - administration & dosage (3) 3
recurrence (3) 3
thrombocytopenia (3) 3
trial (3) 3
tyrosine (3) 3
tyrosine kinase inhibitors (3) 3
aberrant somatic hypermutation (2) 2
adhesion molecules (2) 2
age factors (2) 2
antimetabolites, antineoplastic - adverse effects (2) 2
antineoplastic agents - administration & dosage (2) 2
antitumor effect (2) 2
azacitidine - adverse effects (2) 2
biological response modifiers (2) 2
bone marrow cells - metabolism (2) 2
bone marrow stromal cells (2) 2
cardiac patients (2) 2
cardiovascular diseases - chemically induced (2) 2
cell transformation, neoplastic - genetics (2) 2
chromosomes (2) 2
chronic myelogenous leukemia (2) 2
chronic myelomonocytic leukemia (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 22 - 33
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 05/2015, Volume 125, Issue 5, pp. 1857 - 1872
Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by mutations in genes encoding epigenetic modifiers and aberrant DNA... 
MEDICINE, RESEARCH & EXPERIMENTAL | DNA METHYLATION | MALIGNANT HEMATOPOIESIS | 5-AZA-2'-DEOXYCYTIDINE DECITABINE | METHYLTRANSFERASE GENE EZH2 | CHROMOSOME CONFORMATION | ACUTE MYELOID-LEUKEMIA | EXPRESSION PROFILES | MYELODYSPLASTIC SYNDROMES | RAF/MEK/ERK PATHWAY | EPIGENETIC CHANGES | Genes, Neoplasm | Humans | Leukemia, Myelomonocytic, Chronic - genetics | Middle Aged | Male | Gene Expression Profiling | Leukemia, Myelomonocytic, Chronic - drug therapy | Leukemia, Myelomonocytic, Chronic - metabolism | beta-Thromboglobulin - biosynthesis | DNA Mutational Analysis | Aged, 80 and over | Antimetabolites, Antineoplastic - pharmacology | Female | Platelet Factor 4 - biosynthesis | Neoplasm Proteins - genetics | Gene Expression Regulation, Neoplastic - genetics | Platelet Factor 4 - genetics | Neoplasm Proteins - biosynthesis | beta-Thromboglobulin - genetics | Azacitidine - analogs & derivatives | Treatment Outcome | beta-Thromboglobulin - physiology | DNA, Intergenic - genetics | Azacitidine - pharmacology | Antimetabolites, Antineoplastic - therapeutic use | Drug Resistance, Neoplasm - genetics | Platelet Factor 4 - physiology | Bone Marrow - pathology | Aged | Enhancer Elements, Genetic - genetics | DNA Methylation - drug effects | Azacitidine - therapeutic use | Research | Gene expression | Methylation | Drug therapy | Chronic myelomonocytic leukemia | Enzymes | Clinical trials | Cancer therapies | Generalized linear models | Studies | Medical prognosis | DNA methylation | Epigenetics | Mutation | Deoxyribonucleic acid--DNA | Cancer | Apoptosis | Genetics | Oncology | Immunology | Hematology | Therapeutics
Journal Article
Journal Article
Annals of Hematology, ISSN 0939-5555, 10/2018, Volume 97, Issue 10, pp. 1767 - 1774
Journal Article
Blood, ISSN 0006-4971, 11/2014, Volume 124, Issue 19, pp. 2930 - 2936
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 2012, Volume 5, Issue 1, pp. 44 - 44
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2017, Volume 176, Issue 2, pp. 258 - 267
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1652 - 1652
Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adult patients with resistant or intolerant chronic phase (CP), accelerated... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2931 - 2931
Background: Since its introduction ponatinib has proved great efficacy among patients (pts) with chronic myeloid leukemia (CML), representing in some settings... 
Journal Article